Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch Health Companies Inc.BHC · Entity 4363 | President, U.S. Businesses | May 10, 2022 | May 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch Health Companies Inc.
Report date May 10, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 112,741 |
Ending reported balance
After 2022-05-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-10 · Exercise / conversion · Acquired 8,643 · Balance 99,149 F1: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. F3: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. Row 2 · 2022-05-10 · Exercise / conversion · Acquired 13,592 · Balance 112,741 F2: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. F3: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10 | Direct | 0 |
Reported balance
After 2022-05-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-10 · Grant · Acquired 8,643 · Balance 0 F3: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. F1: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10 | Direct | 0 |
Reported balance
After 2022-05-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-10 · Exercise / conversion · Disposed 8,643 · Balance 0 F3: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. F1: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10 | Direct | 0 |
Reported balance
After 2022-05-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-10 · Grant · Acquired 13,592 · Balance 0 F3: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. F2: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10 | Direct | 0 |
Reported balance
After 2022-05-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-10 · Exercise / conversion · Disposed 13,592 · Balance 0 F3: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. F2: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service.
F2: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service.
F3: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2022 Filed May 13, 2022 01:03 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionRestricted Share Units · Derivative | 13,592 | $9.40 | $127,764.80 |
DisclosureSEC source: 0000899243-22-017876 · doc4.xml · derivative · entry 6 Spurr Robert · CIK 0001543795 · President, U.S. Businesses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. F2 · shares: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. F2 · derivative.exercise_date: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. Read SEC document |
| May 10, 2022 Filed May 13, 2022 01:03 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantRestricted Share Units · Derivative | 13,592 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-017876 · doc4.xml · derivative · entry 5 Spurr Robert · CIK 0001543795 · President, U.S. Businesses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 13,592 shares Expires 2022-05-10 F3 · derivative.exercise_price: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. F2 · shares: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. F3 · price: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. Read SEC document |
| May 10, 2022 Filed May 13, 2022 01:03 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionRestricted Share Units · Derivative | 8,643 | $9.40 | $81,244.20 |
DisclosureSEC source: 0000899243-22-017876 · doc4.xml · derivative · entry 4 Spurr Robert · CIK 0001543795 · President, U.S. Businesses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. F1 · shares: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. F1 · derivative.exercise_date: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. Read SEC document |
| May 10, 2022 Filed May 13, 2022 01:03 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantRestricted Share Units · Derivative | 8,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-017876 · doc4.xml · derivative · entry 3 Spurr Robert · CIK 0001543795 · President, U.S. Businesses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 8,643 shares Expires 2022-05-10 F3 · derivative.exercise_price: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. F1 · shares: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. F3 · price: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. F1 · derivative.exercise_date: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. Read SEC document |
| May 10, 2022 Filed May 13, 2022 01:03 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Shares, No Par Value | 13,592 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-017876 · doc4.xml · nonDerivative · entry 2 Spurr Robert · CIK 0001543795 · President, U.S. Businesses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. F3 · price: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. Read SEC document |
| May 10, 2022 Filed May 13, 2022 01:03 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Shares, No Par Value | 8,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-017876 · doc4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · President, U.S. Businesses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. F3 · price: Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 20:32 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 1,595 | $22.19 | $35,393.05 |
DisclosureSEC source: 0001127602-22-012006 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,506 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 20:39 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 4,846 | $22.20 | $107,581.20 |
DisclosureSEC source: 0001127602-22-009483 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,101 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 22:49 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 4,074 | $23.61 | $96,187.14 |
DisclosureSEC source: 0001127602-22-008498 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,947 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:09 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-Qualified Stock Options (right to purchase) · Derivative | 131,910 | $0.00 Strike: $24.17 | $0.00 |
DisclosureSEC source: 0001127602-22-008251 · form4.xml · derivative · entry 3 Spurr Robert · CIK 0001543795 · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,910 Underlying: Common Shares, No Par Value · 131,910 shares Expires 2032-03-02 F3 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:09 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 35,627 | $24.17 | $861,104.59 |
DisclosureSEC source: 0001127602-22-008251 · form4.xml · nonDerivative · entry 2 Spurr Robert · CIK 0001543795 · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,021 F2 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of Bausch Health Companies Inc. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:09 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 1,595 | $23.37 | $37,275.15 |
DisclosureSEC source: 0001127602-22-008251 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,394 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:08 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionRestricted Share Units · Derivative | 15,615 | $24.35 Strike: $24.35 | $380,225.25 |
DisclosureSEC source: 0000899243-22-008822 · doc4.xml · derivative · entry 6 Spurr Robert · CIK 0001543795 · Director · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:08 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantRestricted Share Units · Derivative | 15,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008822 · doc4.xml · derivative · entry 5 Spurr Robert · CIK 0001543795 · Director · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 15,615 shares Expires 2022-02-27 F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis F2 · price: Each PSU converts into Common Shares on a one-for-one basis F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:08 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 1,651 | $24.35 | $40,201.85 |
DisclosureSEC source: 0000899243-22-008822 · doc4.xml · nonDerivative · entry 4 Spurr Robert · CIK 0001543795 · Director · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,989 F5 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:08 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 5,646 | $24.35 | $137,480.10 |
DisclosureSEC source: 0000899243-22-008822 · doc4.xml · nonDerivative · entry 2 Spurr Robert · CIK 0001543795 · Director · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,268 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:08 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Shares, No Par Value | 15,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008822 · doc4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · Director · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. F2 · price: Each PSU converts into Common Shares on a one-for-one basis Read SEC document |
| February 26, 2022 Filed Mar 3, 2022 02:08 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 1,628 | $24.35 | $39,641.80 |
DisclosureSEC source: 0000899243-22-008822 · doc4.xml · nonDerivative · entry 3 Spurr Robert · CIK 0001543795 · Director · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,640 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units ("RSUs"). Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:36 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 3,251 | $25.02 | $81,340.02 |
DisclosureSEC source: 0001127602-22-005469 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,299 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:55 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 3,251 | $26.63 | $86,574.13 |
DisclosureSEC source: 0000950103-22-000900 · dp165456_4-spurr.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,550 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:36 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 283 | $28.60 | $8,093.80 |
DisclosureSEC source: 0001127602-21-026682 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,801 Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:10 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-Qualified Stock Options (right to purchase) · Derivative | 31,400 | $0.00 Strike: $28.85 | $0.00 |
DisclosureSEC source: 0001127602-21-024867 · form4.xml · derivative · entry 2 Spurr Robert · CIK 0001543795 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,400 Underlying: Common Shares, No Par Value · 31,400 shares Expires 2031-09-01 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:10 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 9,026 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024867 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,084 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of the Issuer Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:09 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 1,278 | $28.95 | $36,998.10 |
DisclosureSEC source: 0001127602-21-024581 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,058 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 23:03 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 32,749 | $0.00 Strike: $32.56 | $0.00 |
DisclosureSEC source: 0001127602-21-009572 · form4.xml · derivative · entry 2 Spurr Robert · CIK 0001543795 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,749 Underlying: Common Shares, No Par Value · 32,749 shares Expires 2031-03-03 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 23:03 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 23,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-009572 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,336 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of Bausch Health Companies Inc. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:50 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 3,252 | $31.42 | $102,177.84 |
DisclosureSEC source: 0001127602-21-009220 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,444 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| October 02, 2020 Filed Oct 6, 2020 20:50 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 276 | $15.89 | $4,385.64 |
DisclosureSEC source: 0001127602-20-026615 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,696 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 22:50 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 1,278 | $17.00 | $21,726.00 |
DisclosureSEC source: 0001127602-20-024487 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,972 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.